GLP-1 Market
LLY $1142.85 ▼ -0.6% NVO $37.32 ▼ -0.2% PFE $27.80 ▼ -1.1% VKTX $29.94 ▼ -1.9% KLRA $10.39 ▼ -5.8% GPCR $27.67 ▼ -4.5% RHHBY $52.23 ▼ -0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

moderate- or high-intensity statin/ rosuvastatin

Company
Wake Forest University Health Sciences
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 3, 2026

Trial details
  • Completed NCT NCT05742841

    EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

    Not yet reported Wake Forest University Health Sciences 22 participants Est. completion 2023-07-15 1 site Stand-alone
    Other conditions: Lipid Disorder
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: moderate- or high-intensity statin/ rosuvastatin, Crestor

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.